Other research analysts also recently issued reports about the stock. Cantor Fitzgerald reissued a hold rating and set a $14.00 price objective on shares of Alder Biopharmaceuticals in a research report on Thursday, May 2nd. Zacks Investment Research downgraded shares of Alder Biopharmaceuticals from a buy rating to a hold rating in a research report on Monday, July 29th. Cowen set a $18.00 price objective on shares of Alder Biopharmaceuticals and gave the stock a buy rating in a research report on Friday, May 3rd. Mizuho reissued a hold rating and set a $15.00 price objective on shares of Alder Biopharmaceuticals in a research report on Friday, May 3rd. Finally, Credit Suisse Group reissued a neutral rating on shares of Alder Biopharmaceuticals in a research report on Wednesday, July 10th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $19.82.
Shares of Alder Biopharmaceuticals stock opened at $8.87 on Friday. Alder Biopharmaceuticals has a 1 year low of $8.81 and a 1 year high of $20.87. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 1.21. The stock’s fifty day simple moving average is $10.91.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Featured Story: What can cause a stock to outperform?
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.